Hester Biosciences Share Price Today (HESTERBIO)
TODAY IN ONE LINE
HESTERBIO slipped 0.6% on average volume, in line with Nifty's -0.9% move, supported by recent strong earnings.
With a market cap of ₹2,068.06 Cr., it trades at a P/E of 37.48. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Hester Biosciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 968.7% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 22.2% and Profit up 993.0%
- ●High Capital EfficiencyROCE of 15.2% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 15.9%
- ●Healthy Operating MarginsOPM is structurally strong at 26.1%
- ●High Promoter HoldingPromoters hold 53.7% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Hester Biosciences News
What changed recently?
Recent events, corporate actions, and announcements.
Hester Biosciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Hester Biosciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Hester Biosciences Limited trades at a P/E of 37.48× and P/B of 5.79×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Hester Biosciences Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Hester Biosciences Limited — derived from the live tape, not yesterday's close.
Hester Biosciences Limited last traded at ₹2,435.9 with an intraday range of ₹2,401–₹2,468.7 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹2435.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2604.80 | +168.90 | +6.93% |
| R3 | 2537.10 | +101.20 | +4.15% |
| R2 | 2502.90 | +67.00 | +2.75% |
| R1 | 2469.40 | +33.50 | +1.38% |
| PIVOT | 2435.20 | -0.70 | -0.03% |
| CURRENT | 2435.90 | — | — |
| S1 | 2401.70 | -34.20 | -1.40% |
| S2 | 2367.50 | -68.40 | -2.81% |
| S3 | 2334.00 | -101.90 | -4.18% |
| S4 | 2266.30 | -169.60 | -6.96% |
HESTERBIO is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹2433.6–₹2468.7
Trading Inside opening range
Hester Biosciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Hester Biosciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Hester Biosciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,068.06 Cr. and reported EPS of ₹65.36.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 311 | 333 ▲ 6.9% |
| Sales Growth YoY %Derived | 2.15% | 6.91% |
| Other Income | 4 | 10 ▲ 146.8% |
| Total Income | 315 | 342 ▲ 8.7% |
| 88 | 82 ▼ 7.2% | |
| Gross ProfitDerived | 223 | 251 ▲ 12.5% |
| Gross Margin %Derived | 71.61% | 75.36% |
| 162 | 164 ▲ 1.4% | |
| EBITDA (Operating Profit)Derived | 61 | 87 ▲ 41.9% |
| OPM %Derived | 19.62% | 26.05% |
| 30 | 33 ▲ 11.0% | |
| Profit Before Tax (PBT) | 35 | 69 ▲ 95.8% |
| 11 | 18 ▲ 70.8% | |
| Effective Tax %Derived | 30.29% | 26.42% |
| Total Profit for Period | 29 | 57 ▲ 99.4% |
| Less: Non-controlling Interests | 1 | 2 ▲ 37.9% |
| Net Profit (Owner's PAT)Derived | 27 | 56 ▲ 102.4% |
| Net Profit Margin %Derived | 8.84% | 16.73% |
| PAT Growth YoY %Derived | 45.52% | 102.41% |
| Earnings Per Share (EPS ₹) | 32.31 | 65.41 ▲ 102.4% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% |
| Share of Profit from Associates/JVs | 4 | 6 ▲ 55.4% |
| Other Comprehensive Income (Net of Tax) | 0 | -2 ▼ 4045.8% |
| Total Expenses (incl. D&A & Interest) | 280 | 273 ▼ 2.4% |
| Material Cost % of RevenueDerived | 20.55% | 21.23% |
| Employee Cost % of RevenueDerived | 20.07% | 18.84% |
| Other Cost % of RevenueDerived | 31.92% | 30.46% |
| Interest Coverage (x)Derived | 3.48x | 6.20x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 178 | 183 ▲ 2.9% | 214 ▲ 16.9% | 235 ▲ 9.6% | 266 ▲ 13.2% | 305 ▲ 14.5% | 311 ▲ 2.2% | 333 ▲ 6.9% | |
| Sales Growth YoY %Derived | — | 2.92% | 16.95% | 9.65% | 13.23% | 14.45% | 2.15% | 6.91% | |
| Other Income | 7 | 6 ▼ 11.7% | 5 ▼ 26.4% | 14 ▲ 193.4% | 15 ▲ 10.3% | 11 ▼ 29.8% | 4 ▼ 63.1% | 10 ▲ 146.8% | |
| Total Income | 185 | 190 ▲ 2.4% | 219 ▲ 15.5% | 249 ▲ 13.6% | 281 ▲ 13.1% | 315 ▲ 12.1% | 315 ▼ 0.1% | 342 ▲ 8.7% | |
29 | 20 ▼ 31.8% | 50 ▲ 154.8% | 63 ▲ 24.9% | 77 ▲ 23.6% | 96 ▲ 23.7% | 88 ▼ 7.9% | 82 ▼ 7.2% | ||
| Gross ProfitDerived | 149 | 164 ▲ 9.6% | 164 ▲ 0.3% | 172 ▲ 5.0% | 189 ▲ 9.5% | 209 ▲ 10.6% | 223 ▲ 6.8% | 251 ▲ 12.5% | |
| Gross Margin %Derived | 83.78% | 89.25% | 76.57% | 73.31% | 70.88% | 68.52% | 71.61% | 75.36% | |
81 | 108 ▲ 33.3% | 95 ▼ 11.7% | 112 ▲ 17.7% | 138 ▲ 22.9% | 155 ▲ 12.3% | 162 ▲ 4.3% | 164 ▲ 1.4% | ||
| EBITDA (Operating Profit)Derived | 68 | 55 ▼ 18.6% | 69 ▲ 23.9% | 60 ▼ 12.6% | 51 ▼ 15.6% | 54 ▲ 6.0% | 61 ▲ 13.8% | 87 ▲ 41.9% | |
| OPM %Derived | 38.21% | 30.23% | 32.03% | 25.52% | 19.02% | 17.62% | 19.62% | 26.05% | |
18 | 20 ▲ 11.2% | 17 ▼ 18.8% | 21 ▲ 24.4% | 30 ▲ 45.4% | 37 ▲ 23.1% | 30 ▼ 20.1% | 33 ▲ 11.0% | ||
| Profit Before Tax (PBT) | 57 | 41 ▼ 27.3% | 50 ▲ 21.2% | 53 ▲ 5.9% | 36 ▼ 32.7% | 27 ▼ 23.5% | 35 ▲ 29.7% | 69 ▲ 95.8% | |
16 | 10 ▼ 36.1% | 15 ▲ 49.2% | 14 ▼ 9.0% | 12 ▼ 13.5% | 11 ▼ 11.0% | 11 ▼ 0.4% | 18 ▲ 70.8% | ||
| Effective Tax %Derived | 28.43% | 24.98% | 30.75% | 26.41% | 33.90% | 39.45% | 30.29% | 26.42% | |
| Total Profit for Period | 41 | 31 ▼ 23.8% | 35 ▲ 11.9% | 39 ▲ 13.8% | 28 ▼ 29.0% | 21 ▼ 24.5% | 29 ▲ 36.2% | 57 ▲ 99.4% | |
| Less: Non-controlling Interests | -1 | 2 ▲ 309.6% | 0 ▼ 85.4% | 0 ▼ 38.8% | 1 ▲ 758.5% | 2 ▲ 61.7% | 1 ▼ 41.2% | 2 ▲ 37.9% | |
| Net Profit (Owner's PAT)Derived | 42 | 29 ▼ 29.8% | 34 ▲ 18.0% | 39 ▲ 14.2% | 27 ▼ 32.3% | 19 ▼ 29.1% | 27 ▲ 45.5% | 56 ▲ 102.4% | |
| Net Profit Margin %Derived | 23.34% | 15.92% | 16.06% | 16.73% | 10.01% | 6.20% | 8.84% | 16.73% | |
| PAT Growth YoY %Derived | — | -29.82% | 18.03% | 14.20% | -32.28% | -29.06% | 45.52% | 102.41% | |
| Earnings Per Share (EPS ₹) | 48.86 | 34.29 ▼ 29.8% | 40.47 ▲ 18.0% | 46.22 ▲ 14.2% | 31.30 ▼ 32.3% | 22.20 ▼ 29.1% | 32.31 ▲ 45.5% | 65.41 ▲ 102.4% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | 0 | 4 ▲ 942.3% | 5 ▲ 4.5% | 4 ▼ 11.0% | 6 ▲ 55.4% | |
| Other Comprehensive Income (Net of Tax) | -0 | 2 ▲ 915.9% | -2 ▼ 177.2% | 1 ▲ 152.0% | 2 ▲ 97.9% | -0 ▼ 102.0% | 0 ▲ 278.8% | -2 ▼ 4045.8% | |
| Total Expenses (incl. D&A & Interest) | 128 | 148 ▲ 15.5% | 169 ▲ 13.9% | 196 ▲ 15.8% | 245 ▲ 25.5% | 288 ▲ 17.2% | 280 ▼ 2.9% | 273 ▼ 2.4% | |
| Material Cost % of RevenueDerived | 16.49% | 16.02% | 18.04% | 25.81% | 19.91% | 17.83% | 20.55% | 21.23% | |
| Employee Cost % of RevenueDerived | 16.25% | 22.18% | 18.16% | 19.29% | 21.05% | 21.06% | 20.07% | 18.84% | |
| Other Cost % of RevenueDerived | 29.33% | 36.83% | 26.37% | 28.50% | 30.81% | 29.84% | 31.92% | 30.46% | |
| Interest Coverage (x)Derived | 8.48x | 5.74x | 8.38x | 10.68x | 3.21x | 1.84x | 3.48x | 6.20x |
Hester Biosciences segment analysis : revenue and profit mix.
Disclosed business segments at Hester Biosciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Hester Biosciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Hester Biosciences Limited.
Our AI distills the core fundamental drivers supporting Hester Biosciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Hester Biosciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 20.38% demonstrates strong cost control and pricing power.
Promoter holding 53.73% signals robust management commitment and long-term alignment.
TTM revenue growth 38.2% outpaces peers, indicating robust market expansion.
Debt-to-equity 0.0054 indicates fortress balance sheet with minimal leverage.
ROE 15.90% reflects efficient capital deployment in shareholder value creation.
Key Risks.
P/E 33.79 indicates premium valuation relative to sector median benchmarks.
Latest quarterly EPS grew 1138% YoY, signaling extreme earnings volatility.
TTM EPS grew 968.7% YoY, reflecting unsustainable profit swings and inconsistency.
ROCE 15.20% lags peer median, indicating weak capital efficiency.
Dividend yield 0.33% offers minimal income to shareholders seeking returns.
Flip Conditions.
Valuation risk. a P/E above 49 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.04. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 11% would indicate weaker capital compounding.
Hester Biosciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Hester Biosciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Hester Biosciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Hester Biosciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Hester Biosciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Hester Biosciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Hester Biosciences Limited stood at 40.5% of traded volume, against a 20-day average of 45.2%.
Hester Biosciences announcements: results, concalls, ratings, M&A.
Filings Hester Biosciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Hester Biosciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 68 documents below.
General Updates
Hester Biosciences Limited has informed the Exchange about Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure…
Copy of Newspaper Publication
Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
Copy of Newspaper Publication
Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Hester Biosciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Corrigendum
Hester Biosciences Limited has informed the Exchange regarding Corrigendum to Notice of Annual General Meeting to be held on July 21, 2026
Investor decks & rating reports.
Hester Biosciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Hester Biosciences has declared, sequenced by announce and record date.
Hester Biosciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Hester Biosciences Limited: business, sector, key facts.
What Hester Biosciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Hester Biosciences Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: HESTERBIO, BSE: 524669.
Hester Biosciences Limited is a prominent Indian company specializing in the manufacturing and trading of veterinary vaccines and animal health products, both domestically and internationally. Their business model is segmented into three key areas: Poultry Healthcare, Animal Healthcare, and Petcare, each contributing significantly to their overall revenue and market presence.
The Poultry Healthcare segment forms a substantial portion of Hester's business, focusing on the production and distribution of a wide range of vaccines targeted at various poultry diseases. These vaccines combat common and serious illnesses affecting poultry flocks, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, Marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. This comprehensive suite of vaccines addresses a significant need within the Indian and international poultry industries, ensuring the health and productivity of poultry farms.
Beyond poultry, Hester's Animal Healthcare segment extends its reach to livestock, providing vaccines to protect against diseases such as goat pox, peste des petits ruminants, brucella abortus, contagious bovine pleuropneumonia (CBPP), and lumpy skin disease. In addition to vaccines, this segment offers a diverse range of animal healthcare products, encompassing biosecurity solutions, therapeutic treatments, herbal supplements, homeopathic remedies, and feed supplements. This integrated approach aims to provide comprehensive health management solutions for livestock farmers.
Finally, Hester's Petcare segment caters to the growing market for pet health products. They offer a variety of formulations addressing various pet health needs, including gut health solutions, NSAIDs for pain relief, joint care formulations, parasiticides, coat nutrition products, grooming aids, and anti-infective treatments. This segment reflects Hester's commitment to expanding its product portfolio to encompass the needs of a broadening consumer base.
Further augmenting its services, Hester Biosciences provides diagnostic services, including seroprofiling kits and operates diagnostic labs specifically for poultry flocks. They also offer specialized programs, such as mastitis control programs for cattle, demonstrating a commitment to proactive health management and disease prevention. In essence, Hester Biosciences acts not only as a manufacturer and trader but also as a provider of comprehensive animal health solutions across various segments of the market, reflecting a vertically integrated business model.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Hester Biosciences Limited (HESTERBIO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Hester Biosciences Limited (HESTERBIO)?
The current share price of Hester Biosciences Limited (HESTERBIO) is ₹2,435.9. Today, the stock has declined by ₹14.10 (0.58%), trading in a range of ₹2,401 to ₹2,468.7. The stock opened at ₹2,450 with a trading volume of 6,145 shares.
02Is Hester Biosciences Limited stock a good investment for long-term?
Hester Biosciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,068.06 crores, P/E ratio of 37.48, ROE of 15.90%, and ROCE of 15.20%. The dividend yield stands at 0.44%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Hester Biosciences Limited stock?
The 52-week high price of Hester Biosciences Limited (HESTERBIO) is ₹2,660, while the 52-week low is ₹1,239.3. Currently trading at ₹2,435.9, the stock is 84.2% away from its 52-week low and 8.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Hester Biosciences Limited stock at the current price?
Whether to buy Hester Biosciences Limited stock at ₹2,435.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.48 and P/B ratio of 5.79. Today's performance shows a loss of 0.58%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Hester Biosciences Limited and when is the next dividend?
Hester Biosciences Limited offers a dividend yield of 0.44%, which means for every ₹100 invested at the current price of ₹2,435.9, you can expect to receive approximately ₹0.44 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Hester Biosciences Limited?
Hester Biosciences Limited's key financial metrics include: P/E Ratio: 37.48, P/B Ratio: 5.79, ROE: 15.90%, ROCE: 15.20%, Dividend Yield: 0.44%, EPS: ₹65.36, Book Value: ₹423.46, and Debt-to-Equity: 0.54. The company's market cap stands at ₹2,068.06 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Hester Biosciences Limited stock performing today in the market?
Hester Biosciences Limited stock opened at ₹2,450 and is currently trading at ₹2,435.9, showing a decline of ₹14.10 (0.58%). The intraday high is ₹2,468.7 and low is ₹2,401. The trading volume stands at 6,145 shares, indicating moderate market participation today.
08What is the P/E ratio of Hester Biosciences Limited and what does it indicate?
Hester Biosciences Limited has a Price-to-Earnings (P/E) ratio of 37.48, which means investors are willing to pay ₹37.48 for every ₹1 of earnings. With an EPS of ₹65.36, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Hester Biosciences Limited (HESTERBIO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.